Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Clinical trial NCT07072585 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07072585
Sponsor: Children's Oncology Group
Status: NOT_YET_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Stage II T Lymphoblastic Leukemia/Lymphoma Stage III T Lymphoblastic Leukemia/Lymphoma Stage IV T Lymphoblastic Leukemia/Lymphoma T Acute Lymphoblastic Leukemia T Lymphoblastic Lymphoma

Start date: 2026-08-28
Primary completion: 2035-09-01
Enrollment: 1708

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.